I can't say I have a well informed opinion here. The drug does seem to have activity on a number of measures despite this poor trial result. Whether or not it has a future might depend on the competitive oral space - if BG-12 succeeds, maybe that will dominate the oral space. Down 50% just felt extreme to me, but it's not a play I'd make myself right now - just not well enough informed in this space.
Market Data 
Markets 
AI
